Prognostic Impact of Expression in Patients with Surgically Resected Lung Adenocarcinoma.

Lung adenocarcinoma (LUAD) acts as the representative histological subtype regarding lung cancer, and its mortality and morbidity remain high. Therefore, more therapeutic targets are needed. Insulin-like growth factor 2 messenger RNA-binding proteins (IGF2BPs), a class of RNA-binding proteins, including , , and , are considered to be the "reader" of N6-methyladenosine (m6A) methylation and remarkably affects cancer occurrence and development. Studies have shown that has prognostic potential in multiple public databases compared with other members of the IGF2BPs family. This research aims to use the expression data of in multiple cohorts to explore the expression as well as prognostic significance of in LUAD. Based on the six datasets from the Oncomine database, LUAD tissue presented obviously higher expression relative to normal tissue. In the three cohorts of The Cancer Genome Atlas (TCGA), Gene expression profiling interactive analysis, and Gene Expression Omnibus, was abnormally highly expressed in LUAD, and it could lead to a weaker prognosis ( < 0.05). The cohort from National Cancer Center of China (NCC) verified the prognostic value of , and the high expression could be remarkably related to gender, tumor length, differentiation, and T stage ( < 0.05). Cox regression analysis of TCGA and NCC cohorts consistently showed that expression could serve for independently predicting the prognosis of LUAD patients ( < 0.05). Ten hallmark pathways with significant enrichment were identified. is abnormally highly expressed in LUAD tissue, and can lead to worse overall survival. In summary, may be an oncogene and potential prognostic biomarker of LUAD.